Molnupiravir_product_DataBase

Bioactivity

Molnupiravir (EIDD-2801) is an orally bioavailable prodrug of the ribonucleoside analog EIDD-1931. Molnupiravir has broad spectrum antiviral activity against influenza virus and multiple coronaviruses, such as SARS-CoV-2, MERS-CoV, SARS-CoV. Molnupiravir has the potential for the research of COVID-19, and seasonal and pandemic influenza[1][2].

In Vivo

Molnupiravir (50-500 mg/kg; p.o.; every 12 hours for 3 days) is robustly antiviral and able to prevent SARS-CoV replication and disease[1].Molnupiravir (7 mg/kg; p.o.; twice daily for 3.5 days) significantly reduces shed virus load and duration of fever[2]. Animal Model:

Name

Molnupiravir

CAS

2492423-29-5

Formula

C13H19N3O7

Molar Mass

329.31

Appearance

Solid

Transport

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Reference

[1]. Sheahan TP, et al. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci Transl Med. 2020 Apr 6. pii: eabb5883. [2]. Toots M, et al. Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia. Sci Transl Med. 2019 Oct 23;11(515). pii: eaax5866.

PeptideDB

Molnupiravir

CAS: 2492423-29-5 F: C13H19N3O7 W: 329.31